Karus Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Karus Therapeutics's estimated annual revenue is currently $930k per year.
- Karus Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Karus Therapeutics has 6 Employees.
- Karus Therapeutics grew their employee count by -33% last year.
Karus Therapeutics's People
| Name | Title | Email/Phone |
|---|
Karus Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Karus Therapeutics?
Karus Therapeutics is a clinical-stage biopharmaceutical company, based in Oxfordshire, UK. We are developing precision medicines to treat cancer patients with a clear unmet medical need and limited treatment options. We currently have two clinical candidates in Phase I studies: KA2507 and KA2237. Our orally-active, small molecule drugs combine targeted and immunotherapeutic mechanisms of action. Read more about our portfolio here: http://karustherapeutics.com/portfolio/
keywords:N/A
N/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Karus Therapeutics News
2022-04-17 - Fragile X Syndrome (FXS) Treatment Market May See a Big Move by ...
... Ovid Therapeutics., BELLUS Health Inc., AMO PHARMA, Neuren Pharmaceuticals, Anavex Life Sciences Corp., Karus Therapeutics and others.
Other Companies in Harwell Campus
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.4M | 21 | -22% | N/A |
#2 | $6.1M | 25 | 19% | N/A |